Clinical Trials Logo

NSCLC clinical trials

View clinical trials related to NSCLC.

Filter by:
  • Not yet recruiting  
  • « Prev · Page 6

NCT ID: NCT02975609 Not yet recruiting - NSCLC Clinical Trials

Phase II Trial of SBRT Compared With Conventional Radiotherapy for Oligometastatic Non-Small Cell Lung Cancer

Start date: November 2016
Phase: Phase 2
Study type: Interventional

This protocol is a phase II randomized controlled trial (RCT) evaluating the efficacy of SBRT compared with conventional fractionated radiotherapy for oligometastatic Non-Small Cell Lung Cancer

NCT ID: NCT02940990 Not yet recruiting - NSCLC Clinical Trials

SBRT in Multi-metastatic NSCLC Patients Which Are Pan-negative for Driver Mutations

Start date: November 2016
Phase: Phase 2
Study type: Interventional

This protocol is a phase II multi-center randomized controlled trial (RCT) evaluating the efficacy of SBRT in multi-metastatic NSCLC patients who are pan-negative for driver mutations.

NCT ID: NCT02766348 Not yet recruiting - NSCLC Clinical Trials

Clinical Efficacy and Safety of Dendritic Cytotoxic Lymphocyte(DC-CTL) Cell Infusion in NSCLC Patients

Start date: May 2016
Phase: Phase 2
Study type: Interventional

Patients in group A will receive DC-CTL treatment and chemotherapy. Patients in group B will receive only chemotherapy.

NCT ID: NCT02387086 Not yet recruiting - NSCLC Clinical Trials

Gefitinib Combined With Thalidomide to Treat NSCLC

Start date: May 2015
Phase: Phase 2/Phase 3
Study type: Interventional

The purpose of this study is to determine whether thalidomide can improve the effectiveness of the gefitinib in NSCLC patients with EGFR mutations.

NCT ID: NCT02385136 Not yet recruiting - NSCLC Clinical Trials

Temozolomide and Concomitant Whole Brain Radiotherapy in NSCLC Patients With Brain Metastases

Start date: April 2015
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to evaluate the safety profile and efficacy of whole brain radiotherapy (WBRT) concomitantly with temozolomide (TMZ) in patients with brain metastases (BM).Patients with BM were randomly assigned to 30 Gy of WBRT with or without concomitant TMZ (75 mg/m2/d) plus two cycles of TMZ (200 mg/m2/d for 5 days).

NCT ID: NCT02226757 Not yet recruiting - NSCLC Clinical Trials

Paclitaxel-trastuzumab in EGFR-mutated NSCLC Patients

Start date: August 2014
Phase: Phase 2
Study type: Interventional

This study is a pilot study in EGFR-mutated NSCLC patients who have progressed on standard-dose TKIs. Tumor biopsies will be evaluated for HER2-expression. In case of HER2 expression, patients can participate in the trial after obtaining informed consent. Patients will be treated with weekly paclitaxel-trastuzumab.

NCT ID: NCT01697163 Not yet recruiting - NSCLC Clinical Trials

De Novo Resistance to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors

Start date: October 2012
Phase: N/A
Study type: Observational

This study is based on the following hypothesis "De novo resistance to EGFR-TKI in EGFR mutation positive patients is related with mutations in EGFR downstream genes". Investigators will prospectively collect genomic DNA and clinical data regarding treatment outcomes to EGFR-TKI in NSCLC patients with activating EGFR mutations. Investigators will sequence candidate mutations of EGFR downstream genes and analyze c-met gene amplification and protein expression in PTEN, HGF, and IGFR. To identify genetic mutations, amplification, and protein over expression as predictive markers of treatment outcomes, investigators analyzed the association of treatment outcomes with the presence of genetic alteration or protein over expression. Investigators will attempt to identify biomarkers that are able to predict de novo resistance to EGFR-TKI in EGFR mutated NSCLC.